A recent success in combating Texas Medicaid fraud will result in $72 million being returned to the state.
The Texas Attorney General’s Office charged Par Pharmaceutical Inc., based in New Jersey, and three other drug manufacturers with defrauding the state’s Medicaid program by improperly reporting drug prices.
Because the defendants provided inaccurate market prices for their drugs, the Medicaid program over-reimbursed pharmacies for Par’s products.
Under the agreement, Par must pay $154 million to resolve enforcement actions filed by Texas and four other states.
